Our Product Research
Sustaining, improving and prolonging human life is what we at Immunimedicor are all about. We are constantly focused on discovering new techniques to develop, license and commercialize innovative biotechnology products. In product research, our goal is to achieve new heights in biotechnology. In our future endeavors, we expect to show the scientific community hundreds of new molecules that have never been seen before by man.
Although, our initial focus is on IM-039-001 and its’ significance as a part of the treatement of Cancer, we expect our other innovative products to play a vital role in the development of genetically engineered pharmaceuticals and to also address urgent needs for:
• Effective treatments for HIV/AIDS;
• Effective treatment for other forms of cancer;
• New antibiotics;
• Advances in Neuroscience;
Although our initial goal is to develop Imucore IM-039-001, a Cancer treatment, it will be followed by further development of IM-039 as a treatment modality for other diseases.
IM-039-001 causes various types of cancer cells to revert to an irreversible non-dividing state. The cancer cell lines tested included malignant melanoma, pancreatic, primary breast tumor, ovarian cancer and osteosarcoma, among other somatic tumor lines. These results made it clear that IM-039 would be an effective treatment for any cell line to which it could be targeted.
Since IM-039-001 was found to be effective against lymphatic somatic and myelitic cell lines without being toxic, it was then tested for effectiveness against T-cells. The desire to keep the IM-039 from affecting healthy cells led to the research and discovery of IM-039 for infected T-cells.
We will be working and supporting many researchers in
pursuing the filing of an investigational new drug application (“IND”)
with the United States Food and Drug Administration (“FDA”)
for IM-039-001.
The IM-039 product removes the treated cell's ability to replicate without
affecting healthy cells.
The technology that IM-039 is based upon will allow Immunomedicor to research and develop a whole new line of novel molecules, never seen by man, to sustain, improve and prolong life.
|
|
| 1. On initial funding we will complete a research
grant to improve the process
by which the IM-039 is separated from its raw material. We will also
sign the lease on the laboratory facility and begin installation
of the equipment critical to the separation and characterization
of the IM-039 from its raw material. Timing: first 30 days. 2. In approximately 30 days from the lease signing, we should
have the first sections of the lab operational and ready to begin
the process of separation and characterization of the IM-039
from its raw material. 3. After about four weeks of work on the separation, we should
have enough working material to begin the first stages of the
preclinical work. 4. Small amounts of the IM-039 will
be shipped to a contract facility to begin the humanization of
IM-039. 5. After roughly 15 weeks of development, the humanized version
of IM-039 will be ready
for testing for toxicity, affinity and effectiveness. 6. One week after completion of the humanized IM-039,
we should be ready to file for patents in both the US and Mexico. 7. Immediately following the filing of the patent applications,
we will begin in vitro testing of the IM-039 against various
cancer lines. 8. After approximately 30 days, we should be able to start our
preclinical small animal studies. 9. Once we have concluded the small animal studies, we should
be able to file our “Innovative New Drug” (IND) application
with the FDA. 10. As we conclude our small animal studies and show no toxicity
and good affinity plus effectiveness, we may begin clinical trials
in a foreign country.
|
